Cellectis CLLS 深 滬
已收盤 10-24 16:00:00 美东时间
3.48
+0.010
+0.29%
華盛通- 最 高3.61
- 今 開3.47
- 成交量 4.41万股
- 最 低 3.47
- 昨 收 3.47
- 總市值 3.48亿
- 52周最高 5.4796
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 1.10
- 委 比 94.98%
- 總股本 10000.00万
- 歷史最高 50.00
- 量 比 0.40
- 振 幅 4.03%
- 歷史最低 0.9628
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
10-20 20:10
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Barclays Maintains Overweight on Cellectis, Raises Price Target to $8
Barclays analyst Gena Wang maintains Cellectis (NASDAQ:CLLS) with a Overweight and raises the price target from $4 to $8.
10-17 21:22
Cellectis Showcases Pipeline Progress at R&D Day
Cellectis SA ( ($CLLS) ) has provided an announcement. On October 16, 2025, Cel...
10-16 19:28
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
Cellectis reported promising Phase 1 data for lasme-cel (UCART22) in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). The study showed an overall response rate (ORR) of 68% with Process 2 (n=22), 83% at the recommended Phase 2 dose (RP2D, n=12), and 100% in the target Phase 2 population (n=9). Safety was generally well-tolerated with manageable adverse events. In the Phase 2 population, 56% achieved complete remission (CR)/CR ...
10-16 19:19
Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers
<b>Event Summary:</b> Cellectis is hosting an R&D Day in New York City to present full Phase 1 data and discuss the pivotal Phase 2 strategy for lasme-cel (UCART22) in r/r B-ALL. <br><br> <b>Event Details:</b> October 16, 2025, 08:30 – 10:30 a.m. ET, in-person and live webcast available. <br> <br> <b>Cellectis Overview:</b> A clinical-stage biotech company developing allogeneic CAR T immunotherapies and gene therapies. <br><br> <b>Webcast:</b> Jo...
10-16 11:00
Allogene licensor Cellectis faces patent lawsuit in the U.S.
Cancer drug developer Allogene Therapeutics (NASDAQ:ALLO) announced on Tuesday that its licensor, Cellectis (NASDAQ:CLLS), is facing a lawsuit in the U.S. over allegations of patent infringement relat...
10-14 22:25
Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress
Cellectis announced advancements in gene therapy at the 2025 ESGCT congress in Sevilla, highlighting the potential of circular single-stranded DNA (CssDNA) as a non-viral template and presenting a comprehensive study on TALEB off-target effects. The CssDNA research demonstrates efficient gene insertion and long-term engraftment in hematopoietic stem cells, while the TALEB study shows minimal off-target editing, supporting safe therapeutic applica...
10-07 06:40
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
09-29 17:07
Top 5 Biotech Stocks With Strong Momentum
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.
08-28 19:19
